• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Colchicine as a potent anti-inflammatory treatment in COVID-19: can we teach an old dog new tricks?

作者信息

Deftereos Spyridon, Giannopoulos George, Vrachatis Dimitrios A, Siasos Gerasimos, Giotaki Sotiria G, Cleman Michael, Dangas George, Stefanadis Christodoulos

机构信息

National and Kapodistrian University of Athens, Athens, Greece.

General Hospital of Athens, 'G.Gennimatas', Athens, Greece.

出版信息

Eur Heart J Cardiovasc Pharmacother. 2020 Jul 1;6(4):255. doi: 10.1093/ehjcvp/pvaa033.

DOI:10.1093/ehjcvp/pvaa033
PMID:32337546
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7197570/
Abstract
摘要

相似文献

1
Colchicine as a potent anti-inflammatory treatment in COVID-19: can we teach an old dog new tricks?秋水仙碱作为COVID-19的一种强效抗炎治疗方法：我们能让老狗学新把戏吗？
Eur Heart J Cardiovasc Pharmacother. 2020 Jul 1;6(4):255. doi: 10.1093/ehjcvp/pvaa033.
2
Colchicine may not be effective in COVID-19 infection; it may even be harmful?秋水仙碱可能对新型冠状病毒肺炎感染无效；甚至可能有害？
Clin Rheumatol. 2020 Jul;39(7):2101-2102. doi: 10.1007/s10067-020-05144-x. Epub 2020 May 11.
3
Amantadine as a drug to mitigate the effects of COVID-19.金刚烷胺作为一种减轻 COVID-19 影响的药物。
Med Hypotheses. 2020 Jul;140:109755. doi: 10.1016/j.mehy.2020.109755. Epub 2020 Apr 25.
4
Treating COVID-19 with colchicine in community healthcare setting.在社区医疗环境中使用秋水仙碱治疗新冠病毒病
Clin Immunol. 2020 Aug;217:108490. doi: 10.1016/j.clim.2020.108490. Epub 2020 May 31.
5
Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial.秋水仙碱对比标准治疗对 COVID-19 住院患者心脏和炎症生物标志物及临床结局的影响：GRECCO-19 随机临床试验。
JAMA Netw Open. 2020 Jun 1;3(6):e2013136. doi: 10.1001/jamanetworkopen.2020.13136.
6
Can Colchicine as an Old Anti-Inflammatory Agent Be Effective in COVID-19?秋水仙碱作为一种古老的抗炎药物，对新冠病毒肺炎是否有效？
J Clin Pharmacol. 2020 Jul;60(7):828-829. doi: 10.1002/jcph.1645. Epub 2020 May 23.
7
Targeting inflammation and cytokine storm in COVID-19.针对新型冠状病毒肺炎中的炎症和细胞因子风暴
Pharmacol Res. 2020 Sep;159:105051. doi: 10.1016/j.phrs.2020.105051. Epub 2020 Jun 27.
8
[Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Should we target the virus, the cell or the disease?].[严重急性呼吸综合征冠状病毒2（SARS-CoV-2）：我们应该针对病毒、细胞还是疾病？]
Virologie (Montrouge). 2020 Jun 1;24(3):135-141. doi: 10.1684/vir.2020.0843.
9
Coronavirus disease 2019 (COVID-19) and anti-rheumatic drugs.2019年冠状病毒病（COVID-19）与抗风湿药物
Rheumatol Int. 2020 May;40(5):825-826. doi: 10.1007/s00296-020-04570-z. Epub 2020 Mar 30.
10
Could IL-17 represent a new therapeutic target for the treatment and/or management of COVID-19-related respiratory syndrome?白细胞介素-17能否成为治疗和/或管理新型冠状病毒肺炎相关呼吸综合征的新治疗靶点？
Pharmacol Res. 2020 Jun;156:104791. doi: 10.1016/j.phrs.2020.104791. Epub 2020 Apr 14.

引用本文的文献

1
[Colchicine, an old friend's perspectives for rheumatology in COVID-19: a scoping review].[秋水仙碱：老朋友对COVID-19中风湿病学的看法：一项范围综述]
Rev Colomb Reumatol. 2022 Jun;29:S35-S47. doi: 10.1016/j.rcreu.2021.02.002. Epub 2021 Mar 27.
2
A brief overview of SARS-CoV-2 infection and its management strategies: a recent update.SARS-CoV-2 感染及其管理策略概述：最新进展。
Mol Cell Biochem. 2024 Sep;479(9):2195-2215. doi: 10.1007/s11010-023-04848-3. Epub 2023 Sep 24.
3
Immunologic Dysregulation and Hypercoagulability as a Pathophysiologic Background in COVID-19 Infection and the Immunomodulating Role of Colchicine.免疫失调和高凝状态作为新冠病毒感染的病理生理背景及秋水仙碱的免疫调节作用
J Clin Med. 2021 Oct 31;10(21):5128. doi: 10.3390/jcm10215128.
4
Races of small molecule clinical trials for the treatment of COVID-19: An up-to-date comprehensive review.治疗 COVID-19 的小分子临床试验的种族差异：最新全面综述。
Drug Dev Res. 2022 Feb;83(1):16-54. doi: 10.1002/ddr.21895. Epub 2021 Nov 11.
5
COVID-19: Failure of the DisCoVeRy Clinical Trial, and Now-New Hopes?新冠病毒肺炎：“发现”临床试验失败，新希望何在？
Pharmaceuticals (Basel). 2021 Jul 11;14(7):664. doi: 10.3390/ph14070664.
6
Repurpose but also (nano)-reformulate! The potential role of nanomedicine in the battle against SARS-CoV2.重新定位，也要（纳米）重塑！纳米医学在抗击 SARS-CoV2 中的潜在作用。
J Control Release. 2021 Sep 10;337:258-284. doi: 10.1016/j.jconrel.2021.07.028. Epub 2021 Jul 20.
7
Repurposing colchicine's journey in view of drug-to-drug interactions. A review.鉴于药物相互作用重新审视秋水仙碱的应用历程。一篇综述。
Toxicol Rep. 2021 Jul 9;8:1389-1393. doi: 10.1016/j.toxrep.2021.07.009. eCollection 2021.
8
The effectiveness of Colchicine as an anti-inflammatory drug in the treatment of coronavirus disease 2019: Meta-analysis.秋水仙碱作为一种抗炎药物治疗 2019 年冠状病毒病的疗效：荟萃分析。
Int J Immunopathol Pharmacol. 2021 Jan-Dec;35:20587384211031763. doi: 10.1177/20587384211031763.
9
The necessity of early anti-inflammatory therapy initiation in cases with mild-to-moderate COVID-19: A personal experience from an attending pharmacist and his resident.在轻症至中度 COVID-19 病例中尽早开始抗炎治疗的必要性：一名药师和他的住院医师的个人经验。
Acta Biomed. 2021 Jul 1;92(3):e2021250. doi: 10.23750/abm.v92i3.11683.
10
COVID-19 in patients with gout on colchicine.痛风患者服用秋水仙碱时的新型冠状病毒肺炎
Rheumatol Int. 2021 Aug;41(8):1503-1507. doi: 10.1007/s00296-021-04902-7. Epub 2021 Jun 5.

本文引用的文献

1
Myocardial localization of coronavirus in COVID-19 cardiogenic shock.COVID-19 心原性休克中冠状病毒的心肌定位。
Eur J Heart Fail. 2020 May;22(5):911-915. doi: 10.1002/ejhf.1828. Epub 2020 Apr 11.
2
The Greek study in the effects of colchicine in COvid-19 complications prevention (GRECCO-19 study): Rationale and study design.希腊研究科维德-19 并发症预防中的秋水仙碱作用（GRECCO-19 研究）：原理和研究设计。
Hellenic J Cardiol. 2020 Jan-Feb;61(1):42-45. doi: 10.1016/j.hjc.2020.03.002. Epub 2020 Apr 3.
3
Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19).COVID-19 患者的致命结局对心血管的影响。
JAMA Cardiol. 2020 Jul 1;5(7):811-818. doi: 10.1001/jamacardio.2020.1017.
4
Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction.心梗后小剂量秋水仙碱的疗效和安全性。
N Engl J Med. 2019 Dec 26;381(26):2497-2505. doi: 10.1056/NEJMoa1912388. Epub 2019 Nov 16.
5
Role of Severe Acute Respiratory Syndrome Coronavirus Viroporins E, 3a, and 8a in Replication and Pathogenesis.严重急性呼吸综合征冠状病毒 viroporins E、3a 和 8a 在复制和发病机制中的作用。
mBio. 2018 May 22;9(3):e02325-17. doi: 10.1128/mBio.02325-17.
6
Editorial: Colchicine: Conventional and Contemporary Indications.社论：秋水仙碱：传统与现代适应症
Curr Pharm Des. 2018;24(6):647. doi: 10.2174/138161282406180510170818.
7
Anti-Inflammatory Treatment With Colchicine in Acute Myocardial Infarction: A Pilot Study.秋水仙碱治疗急性心肌梗死的抗炎作用：一项初步研究。
Circulation. 2015 Oct 13;132(15):1395-403. doi: 10.1161/CIRCULATIONAHA.115.017611. Epub 2015 Aug 11.
8
Colchicine and the heart: pushing the envelope.秋水仙碱与心脏：开拓新领域。
J Am Coll Cardiol. 2013 Nov 12;62(20):1817-25. doi: 10.1016/j.jacc.2013.08.726. Epub 2013 Sep 11.
9
Microtubule-driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasome.微管驱动的线粒体空间排列促进 NLRP3 炎性小体的激活。
Nat Immunol. 2013 May;14(5):454-60. doi: 10.1038/ni.2550. Epub 2013 Mar 17.